These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 33965965

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.
    Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.
    J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The diagnostic accuracy of 68 Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis.
    Rajwa P, Heidenreich J, Drzezga A, Schmidt M, Shariat SF, Heidenreich A.
    Prostate; 2024 Jan 07; 84(1):74-78. PubMed ID: 37750292
    [Abstract] [Full Text] [Related]

  • 26. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb 07; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 27. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer.
    Madendere S, Kılıç M, Köseoğlu E, Aykanat İC, Eden AB, Coşkun B, Tekkalan FB, Balbay MD.
    Urol Oncol; 2024 Feb 07; 42(2):29.e9-29.e15. PubMed ID: 38114351
    [Abstract] [Full Text] [Related]

  • 28. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
    Rahman LA, Rutagengwa D, Lin P, Lin M, Yap J, Lai K, Mancuso P, Rathore P, Haghighi K, Gassner P, Wong LH, Lalak N.
    Cancer Imaging; 2019 Dec 11; 19(1):86. PubMed ID: 31829288
    [Abstract] [Full Text] [Related]

  • 29. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
    Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM.
    Eur Urol Focus; 2020 Sep 15; 6(5):967-974. PubMed ID: 30826284
    [Abstract] [Full Text] [Related]

  • 30. The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
    Meijer D, de Barros HA, van Leeuwen PJ, Bodar YJL, van der Poel HG, Donswijk ML, Hendrikse NH, van Moorselaar RJA, Nieuwenhuijzen JA, Oprea-Lager DE, Vis AN.
    J Urol; 2021 Jun 15; 205(6):1655-1662. PubMed ID: 33530746
    [Abstract] [Full Text] [Related]

  • 31. [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy.
    Schumacher MC, Radecka E, Hellström M, Jacobsson H, Sundin A.
    Scand J Urol; 2015 Feb 15; 49(1):35-42. PubMed ID: 25001948
    [Abstract] [Full Text] [Related]

  • 32. Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer.
    Kubilay E, Akpinar Ç, Oǧuz ES, Araz MS, Soydal Ç, Baltacı S, Ürün Y, Süer E.
    Urol Oncol; 2022 Sep 15; 40(9):408.e19-408.e25. PubMed ID: 35902300
    [Abstract] [Full Text] [Related]

  • 33. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Sep 15; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 34. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
    Haxhimolla J, Kua B, Gilbourd D, Haxhimolla H.
    Semin Oncol Nurs; 2020 Aug 15; 36(4):151044. PubMed ID: 32723519
    [Abstract] [Full Text] [Related]

  • 35. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.
    Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.
    Prostate; 2015 Dec 15; 75(16):1934-40. PubMed ID: 26356236
    [Abstract] [Full Text] [Related]

  • 36. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
    Amiel T, Würnschimmel C, Heck M, Horn T, Nguyen N, Budäus L, Knipper S, Wenzel M, Rauscher I, Eiber M, Wang H, Maurer T.
    J Urol; 2021 Jun 15; 205(6):1663-1670. PubMed ID: 33535796
    [Abstract] [Full Text] [Related]

  • 37. Comparing the Diagnostic Performance of Multiparametric Prostate MRI Versus 68Ga-PSMA PET-CT in the Evaluation Lymph Node Involvement and Extraprostatic Extension.
    Arslan A, Karaarslan E, Güner AL, Sağlıcan Y, Tuna MB, Kural AR.
    Acad Radiol; 2022 May 15; 29(5):698-704. PubMed ID: 32768351
    [Abstract] [Full Text] [Related]

  • 38. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep 15; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

  • 39. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
    Dekalo S, Kuten J, Mintz I, Fahoum I, Gitstein G, Keizman D, Sarid D, Matzkin H, Mabjeesh NJ, Beri A, Even-Sapir E, Yossepowitch O, Mano R.
    Prostate Cancer Prostatic Dis; 2021 Sep 15; 24(3):910-916. PubMed ID: 33790418
    [Abstract] [Full Text] [Related]

  • 40. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Salomon L, Ploussard G, Tilki D, EAU-YAUWP.
    J Urol; 2020 Feb 15; 203(2):338-343. PubMed ID: 31437119
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.